The portfolio of Egis is expanded with the development and production of active materials

By: Trademagazin Date: 2023. 10. 24. 09:00

Egis Gyógyszergyár Zrt., celebrating the 110th anniversary of its foundation this year, is expanding its usual range of activities with new elements, thanks to the fact that in the past period it has made investments in Hungary totaling over HUF 100 billion. Egis Pharma Services, which is considered one of the leading generic pharmaceutical companies in Eastern and Central Europe, now offers active ingredient development and active ingredient manufacturing services to its existing and new pharmaceutical industry partners.

Egis – which conducts research and development activities exclusively in Hungary and manufactures 100% of its products here – already years ago, with a series of conscious investments, began to build the capacities behind the new service: in the last decade, it has made investments in Hungary totaling over HUF 100 billion.

Among the developments, the active ingredient production modernization, which was implemented in two stages between 2015-2019, will be implemented in 2022 by the so-called It was supplemented by investments in the development and production of Highly Potent active ingredients. These preparations, which are used in the treatment of cancer and rheumatic arthritis, among other things, have significant biological activity even at very low doses.